文献速递帕金森病与运动障碍

多巴胺转运体显像可作为帕金森病客观监测生物标志物

Dopamine Transporter Imaging as Objective Monitoring Biomarker in Parkinson's Disease.
PubMed 文献 · Ann Neurol · 2025-03-27

本研究基于PPMI数据库719例帕金森病患者(443男276女,平均年龄62.2±9.5岁,共1981个数据点),采用线性混合模型分析多巴胺转运体(DaT)信号下降与运动症状加重的纵向关系。结果显示,较不受影响侧壳核DaT信号下降与对侧身体运动症状加重显著相关,且不受是否纳入震颤评分影响。研究支持重复DaT显像用于客观监测帕金森病进展。

要点

  • 较不受影响侧壳核DaT信号下降与对侧运动症状加重显著相关。
  • 该关联在纳入或排除震颤评分时均独立存在。
  • 研究支持重复DaT显像用于客观监测帕金森病进展。

核心结论

  • 较不受影响侧壳核DaT信号下降与对侧身体运动症状加重显著相关,且不受是否纳入震颤评分影响。
  • 研究结果支持使用重复DaT显像客观监测帕金森病进展。

研究设计与样本

  • 队列研究,纳入符合MDS帕金森病诊断标准、具有纵向影像和临床数据的参与者,数据来自帕金森病进展标志物计划数据库。
  • 共纳入719例参与者(443例男性、276例女性;平均年龄62.2±9.5岁),共1981个可用数据点。
  • 采用线性混合模型分析DaT信号下降与运动症状严重程度增加随时间的关联。

主要发现

  • 较不受影响侧壳核DaT信号下降与对侧身体运动症状加重显著相关,该关联在纳入或排除震颤评分时均独立存在。
  • 额外模型探索了不同脑区(尾状核与壳核)、症状类别(含或不含震颤条目的MDS UPDRSIII评分)及起病侧别(左或右半球)的影响。

临床怎么用

  • 研究结果支持使用重复DaT显像客观监测帕金森病进展。
  • 该方法未来可能有助于个体化疾病追踪、亚型分型和干预试验。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although dopamine transporter (DaT) imaging is a valuable diagnostic biomarker, few studies have investigated its utility in objectively monitoring disease progression in patients with Parkinson's disease (PD). To date, no study has established a longitudinal relationship between the DaT signal decline and the motor symptom increase, potentially due to neglected factors such as brain regions, disease laterality, and symptom subtypes, which this study addresses. METHODS: This cohort study included participants who met the Movement Disorder Society (MDS) criteria for PD, with longitudinal imaging and clinical data from the Parkinson's Progression Markers Initiative Database. Linear mixed model analyses were used to investigate the relationship between the DaT signal decline and the motor symptom severity increase over time. We hypothesized that a decline in putaminal DaT availability in the less affected hemisphere would be associated with increasing contralateral motor symptoms, measured by the Unified Parkinson's Disease Rating Scale (UPDRS). Additional models explored the effects of different brain regions (caudate and putamen), symptom categories (MDS UPDRSIII score with and without tremor items), and disease onset laterality (left or right hemisphere). RESULTS: We included 719 participants (443 male patients and 276 female patients; mean age = 62.2 ± 9.5 years) with 1,981 available data points. As hypothesized, we observed a significant association between the decrease in the less affected putaminal DaT signal and motor symptom increase in the contralateral body side, independent of including or excluding tremor scores. INTERPRETATION: Our findings support the use of repetitive DaT imaging for objectively monitoring PD progression. This could facilitate personalized disease tracking, subtyping, and intervention testing in the future. ANN NEUROL 2025;98:120-135.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Dzialas V, Bischof GN, Möllenhoff K, et al. Dopamine Transporter Imaging as Objective Monitoring Biomarker in Parkinson's Disease. Ann Neurol. 2025. PMID: 40145540. doi:10.1002/ana.27223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。